Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

00 mg/2,500 mg, and one dose-limiting incident of diarrhea at 2,000 mg/2,500 mg) were transient and medically manageable. The most frequently reported treatment-related grade 2/3 adverse events were hand-foot syndrome (29 percent), leukopenia/neutropenia (24 percent) and fatigue (19 percent).

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modi
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... marketed as XIAFLEX ® in the U.S. and XIAPEX ... Tom Wegman , will present a corporate overview at ... Industry Conference. The presentation will take place ... the Millennium Broadway Hotel in New York, NY ...
(Date:9/19/2014)... Tenn. , Sept. 19, 2014  Over 200 ... the Future to Benefit the Radiation Oncology Institute (ROI), ... held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... we have raised over $70,000 for the ROI this ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the ... clinical trial of the triplet combination of ... the,first-line treatment of advanced non-small cell lung ... significant,improvement in both progression-free survival and overall ...
... Antiproliferative and Antiangiogenic Activity Demonstrated in,Preclinical ... Md., April 17, 2007 /PRNewswire-FirstCall/ --,EntreMed, ... developing,therapeutics for the treatment of cancer ... of preclinical data for its,clinical-stage product ...
Cached Medicine Technology:Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 2EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 3EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 4
(Date:9/20/2014)... 20, 2014 Plumbing construction services ... of 5, indicating a moderately favorable purchasing environment for ... reflects current and future pricing trends that will limit ... Other factors that negatively affect buyer power are a ... and the moderate switching costs. Buyers benefit, however, from ...
(Date:9/20/2014)... Final Cut Pro X Plugin developers ... Information theme for FCPX filmmakers. , “Fun, cool, and simple ... theme,” says Christina Austin, CEO of Pixel Film Studios. “It ... Information features easy to use controls that give the user ... the background color, color of each circle outline, the position ...
(Date:9/20/2014)... September 20, 2014 MarijuanaDoctors.com recently ... showing at the PAIN Week conference that was ... and Casino in Las Vegas from September 2nd ... attended PAIN Week in the hopes of educating ... viable and legitimate tool to treat chronic Pain, ...
(Date:9/19/2014)... DC) (PRWEB) September 19, 2014 “Copay ... inflate sales of brand drugs among patients with prescription ... according to a new report from the ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers from ... subsidized by the federal government. , The report highlights ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- As kids ... the targets of cyberbullies, according to a recent study. ... grades 5 through 8 found that verbal and physical ... patterns vary, bullying intervention and prevention strategies must address ... bullying among boys and girls, the researchers said. The ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... , , , FOSTER ... WHAT: Siperian, Inc., a leading industry provider of a multidomain master ... IBM Global Business Services and Boehringer Ingelheim have teamed up for an ... Most Valuable?" Hussain Mooraj, vice president, Healthcare ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- At ... September 10, reporters were informed that the,First World Conference ... Physicians) and the First World Endoscopy Technology Expo,will be ... Professor Zhang Yangde, the chief ...
... HBV genotypes as well as mutations in the core promoter, ... association with the clinical outcome of liver disease, however, this ... the HBV genotype distribution in certain region. So far, there ... country with a big population and a relatively high HBV ...
... , , MENLO PARK, ... label-free technology that accelerates the development of biotherapeutic and pharmaceutical ... and Read Immunogenicity Assay Kit for rapid detection of anti-drug ... new assay kit provides life science researchers with new levels ...
... , , , NEW YORK, ... has received Orphan-Drug designation from the U.S. Food and Drug Administration ... announced that it had reached an agreement with the FDA regarding ... 3 trial in relapsed/refractory multiple myeloma and that the study is ...
... study finds supervised exercise has better results , WEDNESDAY, ... than shockwave treatment for relieving chronic shoulder pain, according ... used to treat shoulder pain, even though a number ... investigate, Norwegian researchers studied 104 men and women, aged ...
Cached Medicine News:Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 2Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 3Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 4Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 5Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 3Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 4Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... is a fully automated, upgradeable platform ... gas analyzer along with a customer ... freedom to focus on patient care. ... that are essential to efficient blood ...
... Helmer Platelet Agitators feature ... with non-slip texture coating ... circulation for your platelets. ... to be used in ...
... agitators offer a wide range of storage ... drawer storage platform to agitate smoothly, eliminating ... down and squeak. Sturdy, one-piece perforated drawers ... circulation for your platelets., ,i.Series platelet agitators ...
Medicine Products: